Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates With Patients With Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates With Patients With Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept
Glucotrack ADCES海報強調超過50%的調查糖尿病患者接受新的持續血糖監測概念。
Rutherford, NJ, Aug. 15, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology innovator focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced new findings from a recent market research study evaluating the acceptance of its new Continuous Blood Glucose Monitor (CBGM) concept among people with insulin-requiring diabetes. The poster was presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference held Aug. 9-12, 2024, in New Orleans.
醫療科技創新公司Glucotrack(納斯達克股票代碼:GCTK)在糖尿病患者的市場調查研究中發佈了其新型連續血葡萄糖監測器(CBGM)概念的新發現。這張研究海報在2024年8月9日至12日舉辦的美國糖尿病護理與教育專家協會(ADCES)2024年度年會上展出,該會議於2024年8月15日在新奧爾良舉行。
The study, conducted with a diverse group of participants, revealed that over 50% of respondents are open to adopting Glucotrack's new CBGM concept – a small device placed under the skin. This technology is designed to offer continuous, accurate blood glucose monitoring for up to 3 years without the calibration, comfort and wearability challenges associated with traditional Continuous Glucose Monitor (CGM) approaches.
該研究與多樣性參與者一起進行,結果顯示超過50% 的調查對象願意採納Glucotrack的新的CBGm概念——一個放置在皮下的小型設備。該技術旨在提供連續、準確的血糖監測,長達3年且無需校準、舒適性和穿戴難題,這是傳統持續血糖監測 (CGM) 方法不具備的。最具吸引力的前三個方面爲:長期傳感器壽命(該研究測試了兩年的傳感器壽命)、無需佩戴組件和提供實時血糖讀數。這些前三個方面在所有受調查者中都保持一致。
Key features that garnered the most interest include the long-term sensor life (2-year sensor-life was tested during the study), the absence of a wearable component, and the provision of real-time blood glucose readings. These top three appealing aspects were consistent across all segments of respondents.
最吸引人的關鍵特點包括長期傳感器壽命(在研究中測試了2年的傳感器壽命)、無需佩戴組件和提供實時血糖讀數。這三個最吸引人的方面在所有受訪者中均一致。
The study included 757 respondents with intensive insulin therapy (49% type 1 diabetes and 51% type 2 diabetes), comprised of current CGM users (67%), non-users (25%) and ex-users (8%). Respondents used various insulin delivery methods: multiple daily injections (60%) and insulin pump (40%, including 21% automated insulin delivery or AID and 19% non-AID).
該研究共涉及757名使用強化胰島素治療的受訪者(49%爲1型糖尿病,51%爲2型糖尿病),包括目前使用CGm的用戶(67%)、非用戶(25%)和前用戶(8%)。受訪者使用不同的胰島素注射方法:多次日常注射(60%)和胰島素泵(40%,包括21%的自動胰島素注射或AID和19%的非AID)。
"This market research shows us that there is clear need for innovation in continuous glucose monitoring and that Glucotrack's innovative approach has tremendous market potential as it addresses unmet needs," said Paul Goode, President & CEO at Glucotrack. "Our goal has always been to develop innovative solutions that improve the quality of life for people with diabetes. The insights gained from this study will be invaluable as we continue to refine our CBGM technology to better meet the needs of our users."
「這項市場調研向我們展示了連續血糖監測需要創新的明確需求,而Glucotrack的創新方法在市場中具有巨大的潛力,因爲它解決了未滿足的需求,」 Glucotrack總裁兼首席執行官Paul Goode表示。「我們的目標一直是開發創新解決方案,以提高糖尿病患者的生活質量。從這項研究中獲得的見解將在我們繼續完善CBGm技術以更好地滿足我們的用戶需求時發揮寶貴的作用。」
The new CBGM concept represents a significant advancement in diabetes management, offering a more convenient and less intrusive way for individuals to monitor their blood glucose levels. Glucotrack remains committed to leveraging cutting-edge technology to empower people with diabetes to live healthier, more independent lives.
新的CBGm概念代表着糖尿病管理的一個重大進展,爲個人監測他們的血糖水平提供了一種更方便、不受干擾的方法。Glucotrack致力於利用尖端技術使糖尿病患者具有更健康、更獨立的生活方式。
Glucotrack, Inc. has recently made significant strides in its clinical progress. The company successfully completed a 60-day long-term preclinical study of its implantable CGM, demonstrating the feasibility of glucose monitoring in the epidural space. Additionally, a 90-day preclinical study confirmed the sustained accuracy of its CBGM, with a mean absolute relative difference of 4.7%, which is considered highly accurate for a continuous glucose monitor. These advancements pave the way for upcoming human clinical trials that the company plans to initiate later this year, marking a crucial step towards providing a more convenient and discreet glucose monitoring solution for people with diabetes.
Glucotrack, Inc.在其臨床進展方面近期取得了顯著進展。該公司成功完成了一項爲期60天的其可植入的CGM的長期臨床前研究,證明了在硬膜外腔中監測葡萄糖的可行性。此外,90天的臨床前研究確認了其CBGm的持續準確性,其平均相對絕對差異爲4.7%,在持續血糖監測中被認爲具有高度的準確性。這些進展爲公司計劃於今年晚些時候啓動的即將到來的人體臨床試驗鋪平了道路,標誌着提供更方便、更隱蔽的血糖監測解決方案的關鍵一步。
For more information about Glucotrack's CBGM, visit glucotrack.com.
有關Glucotrack CBGm的更多信息,請訪問 glucotrack.com.
# # #
# # #
About Glucotrack, Inc.
關於Glucotrack,Inc。
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack,Inc.(納斯達克代碼:GCTK),專注於爲糖尿病患者設計、開發和商業化新技術。該公司目前正在開發一種長期可植入的連續血糖監測系統,以幫助糖尿病患者。
Glucotrack's CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit .
Glucotrack的CBGM是一個長期可植入的系統,它通過傳感器持續測量血糖水平,在設備使用壽命超過2年的情況下,無需佩戴任何物品並進行最少的校準。更多信息,請訪問.
Forward-Looking Statements
前瞻性聲明
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "believe", "expect", "plan" and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack's results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack's future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
本新聞稿包含《1995年私人證券訴訟改革法案》(Private Securities Litigation Reform Act of 1995)規定的前瞻性聲明。本新聞稿中的陳述可能會被視爲前瞻性陳述。這些非歷史性陳述是基於管理層的信念和管理層目前已獲得的信息所做的假設。這些聲明僅涉及發表聲明的時間內的事件,Glucotrack無需公開更新任何前瞻性陳述,無論是因爲新信息、未來事件或其他原因,除非依據法律規定。本新聞稿中所做的所有前瞻性陳述均受到這些警示性聲明的限制,而且Glucotrack無法保證Glucotrack預期的實際結果將實現或即使實現了也會對我們或我們的業務或運營產生預期的後果或影響。讀者應注意,某些重要因素可能會影響Glucotrack的實際結果,並導致這些結果與本新聞稿中可能做出的任何前瞻性陳述不同。可能影響Glucotrack結果的因素包括但不限於,Glucotrack籌集資金以資助其運營的能力(無論是通過公開股票或私人股票融資、債務融資、戰略合作還是其他方式);有關審批的接受(和時間)的風險(包括美國食品和藥物管理局的批准);有關患者登記和臨床試驗進行的風險;有關Glucotrack未來分銷協議的風險;有關其能夠聘用和留住合格人員,包括銷售和分銷人員的風險;以及在Glucotrack向美國證券交易委員會(SEC)提交的備案申明書中所述風險還有其他附加風險因素。
Contacts:
聯繫人:
Investor Relations:
investors@glucotrack.com
投資者關係:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
媒體:
GlucotrackPR@icrinc.com